PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN, PROCESSES FOR THEIR OBTAINMENT AND METHOD OF TREATING INTESTINAL DISEASE

摘要

Disclosed herein are methods of treating a patient having an intestinal disorder, the methods comprising: administering to a patient in need thereof a pharmaceutical composition comprising a hydrate or solvate form of rifaximin in polymorphic form β, alone or in a mixture with other crystalline, hydrate, solvate or amorphous forms of rifaximin, in gastroresistant microgranules, wherein the rifaximin is administered at a dose of at least 800 mg per day for a period of at least 7 days.

主权项

1. A method of treating a patient having Crohn's disease or an intestinal disorder caused by bacterial infection, the method comprising:
administering to the patient in need thereof a pharmaceutical composition in gastroresistant tablet form comprising a hydrate or solvate form of rifaximin in polymorphic form β, in gastroresistant microgranules, wherein the rifaximin is administered at a dose of from 800 mg to 2400 mg per day for a period of at least 7 days; and wherein the pharmaceutical composition is formulated to provide a maximum plasma concentration (Cmax) of rifaximin of less than 7 ng/mL after seven days of administration and release of rifaximin in the intestinal tract.